RISK-FACTORS FOR SURVIVAL FOLLOWING COMBINED HEART-LUNG TRANSPLANTATION - THE FIRST 100 PATIENTS

被引:34
作者
SHARPLES, LD
SCOTT, JP
DENNIS, C
HIGENBOTTAM, TW
STEWART, S
WREGHITT, T
LARGE, SR
WELLS, FC
WALLWORK, J
机构
[1] UNIV FORVIE SITE,INST PUBL SITE,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,CAMBS,ENGLAND
[2] PAPWORTH HOSP,DEPT RESP PHYSIOL,CAMBRIDGE CB3 8RE,ENGLAND
[3] ADDENBROOKES HOSP,PUBL HLTH LAB SERV,DEPT MICROBIOL,CAMBRIDGE CB2 2QW,ENGLAND
[4] MAYO CLIN & MAYO FDN,DIV THORAC MED,ROCHESTER,MN 55905
关键词
D O I
10.1097/00007890-199401001-00011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
As the numbers of heart and lung transplant recipients have increased it has become possible to identify major risk factors for early (within 3 months) and later (after 3 months) death after this procedure. For 100 patients receiving organs between April 1984 and February 1991, and followed up until February 1992, patient characteristics, operative details, and early morbidity were assessed for their effects on early and later deaths. Recipient age, sex, and preoperative diagnosis did not have a significant effect on early (within 3 months) or later death. Positive cytomegalovirus antibody status of donor or recipient conferred greater risk of death within 90 days (odds ratio [OR]=3.24, P=0.06). Greater than 2 L blood in the first 24 hr after operation (OR=6.00, P=0.05), and ventilation for greater than 24 hr (OR=4.87, P=0.006) were significant prognostic indicators of early death. After the first 3 months, the main risk factor for death was rejection in the first 3 months (OR=1.38 per episode, P=0.008). Early infection in general and CMV infection in particular were associated with a small increase in risk. This study confirms the importance of matching donor and recipient for CMV and shows that difficulties during operation, reflected in postoperative bleeding and ventilation times increased the chance of early death. Later death was associated with early acute rejection. A detrimental effect of infection, including CMV infection, either does not exist, or is too small to be detected in a study of this size.
引用
收藏
页码:218 / 223
页数:6
相关论文
共 26 条
[1]  
BRESLOW NE, 1980, METHODS CANCER RES, V1
[2]  
COX DR, 1972, J R STAT SOC B, V34, P187
[3]  
DAUBER JH, 1990, CLIN CHEST MED, V11, P291
[4]   TREATMENT OF END-STAGE CHRONIC OBSTRUCTIVE PULMONARY-DISEASE WITH DOUBLE LUNG TRANSPLANTATION [J].
EMERY, RW ;
GRAIF, JL ;
HALE, K ;
EALES, F ;
VONRUEDEN, TJ ;
PRITZKER, MR ;
LOVE, K ;
AROM, KV .
CHEST, 1991, 99 (03) :533-537
[5]   EVALUATION OF A COMMERCIAL LATEX AGGLUTINATION-TEST FOR DETECTING ANTIBODIES TO CYTOMEGALOVIRUS IN ORGAN DONORS AND TRANSPLANT RECIPIENTS [J].
GRAY, JJ ;
ALVEY, B ;
SMITH, DJ ;
WREGHITT, TG .
JOURNAL OF VIROLOGICAL METHODS, 1987, 16 (1-2) :13-19
[6]  
HILL AB, 1984, SHORT TXB MED STATIS
[7]   HEART-LUNG TRANSPLANTATION - BETTER USE OF RESOURCES [J].
HUTTER, JA ;
DESPINS, P ;
HIGENBOTTAM, T ;
STEWART, S ;
WALLWORK, J .
AMERICAN JOURNAL OF MEDICINE, 1988, 85 (01) :4-11
[8]  
KAYE MP, 1992, J HEART LUNG TRANSPL, V11, P599
[9]   CYTOMEGALOVIRUS SEROLOGIC STATUS AND POSTOPERATIVE INFECTION CORRELATED WITH RISK OF DEVELOPING CHRONIC REJECTION AFTER PULMONARY TRANSPLANTATION [J].
KEENAN, RJ ;
LEGA, ME ;
DUMMER, JS ;
PARADIS, IL ;
DAUBER, JH ;
RABINOWICH, H ;
YOUSEM, SA ;
HARDESTY, RL ;
GRIFFITH, BP ;
DUQUESNOY, RJ ;
ZEEVI, A .
TRANSPLANTATION, 1991, 51 (02) :433-438
[10]  
KHAGHANI A, 1991, J HEART LUNG TRANSPL, V10, P15